The World Health Organization plans to led a program which ensures poor countries get fair access to Covid-19 tests, treatments and vaccines. WHO aims to deliver antiviral drugs for the patients suffering from mild symptoms and price it minimum $10 per course.
Many drugs to treat mild patients are being developed and one of them is the Merck & Co’s experimental pill molnupiravir.
According to reports, WHO outlines the goals of the Access to Covid-19 Tools Accelerator (ACT-A) until September 2022 and the program wants to deliver more than one billion Covid-19 tests to poor nations. They also want to procure drugs to treat around 120 million patients globally, out of about the new 200 million cases, which is estimated in the next twelve months.
The plan is still a draft and is under consultation and officials declined to comment before it is finalized and will also be sent to global leaders ahead of a G20 summit in Rome at the end of this month.
ACT-A will request the G20 and other donors for funding of $22.8 billion until September next year which is needed to buy and distribute drugs, vaccines and tests to poor nations and minimize the huge gaps in supply between wealthy and less advanced nations.